{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:26:51Z","timestamp":1772778411903,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.trim.2024.102037","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:26:58Z","timestamp":1710606418000},"page":"102037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"84","author":[{"given":"Fang","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2024.102037_bb0005","doi-asserted-by":"crossref","first-page":"1612702","DOI":"10.1155\/2022\/1612702","article-title":"The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the global burden of disease 2019 study and projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0010","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2024.102037_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0020","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1182\/blood-2018-99-111839","article-title":"The real-world incidence of relapse in acute myeloid leukemia (AML): a systematic literature review (SLR)","volume":"132","author":"Oliva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trim.2024.102037_bb0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clml.2022.08.014","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a single-Centre experience","volume":"23","author":"Kopinska","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.trim.2024.102037_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.12998\/wjcc.v11.i2.268","article-title":"Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: an overview of obstacles and opportunities","volume":"11","author":"Chen","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.trim.2024.102037_bb0040","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","article-title":"Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes","volume":"56","author":"Yanada","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102037_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Ozdemir","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.trim.2024.102037_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0055","first-page":"183","article-title":"The guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse\/refractory) in China (2017)","volume":"38","author":"Leukemia, C.S.o.H.C.M.A. Lymphoma Group","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.trim.2024.102037_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123488","article-title":"Immunomodulatory effects associated with Cladribine treatment","volume":"10","author":"Fissolo","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.trim.2024.102037_bb0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/bi00216a032","article-title":"Effects of 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate on DNA synthesis in vitro by purified bacterial and viral DNA polymerases","volume":"30","author":"Hentosh","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.trim.2024.102037_bb0070","first-page":"915","article-title":"Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells","volume":"49","author":"Hirota","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.trim.2024.102037_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","article-title":"Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes","volume":"75","author":"Seto","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trim.2024.102037_bb0080","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S207425","article-title":"Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.trim.2024.102037_bb0085","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","article-title":"Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia","volume":"95","author":"Park","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.trim.2024.102037_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/10428194.2020.1821009","article-title":"Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed\/refractory acute myeloid leukemia","volume":"62","author":"Mushtaq","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trim.2024.102037_bb0095","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4149\/neo_2021_210426N573","article-title":"A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed\/refractory acute myeloid leukemia","volume":"68","author":"Sun","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.trim.2024.102037_bb0100","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ijc.34419","article-title":"Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"152","author":"Tong","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trim.2024.102037_bb0105","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00277-018-3453-z","article-title":"Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia","volume":"97","author":"Xiao","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.trim.2024.102037_bb0110","doi-asserted-by":"crossref","first-page":"1003908","DOI":"10.3389\/fonc.2022.1003908","article-title":"Total marrow irradiation (TMI): addressing an unmet need in hematopoietic cell transplantation - a single institution experience review","volume":"12","author":"Wong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0115","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2024.102037_bb0120","first-page":"825","volume":"vol. 15","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102037_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of health consensus development project on criteria for clinical trials in Chronic Graft-versus-Host Disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.trim.2024.102037_bb0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00277-014-2143-8","article-title":"Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia","volume":"93","author":"De Astis","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.trim.2024.102037_bb0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-019-03792-8","article-title":"FLAG vs FLAG-IDA: outcomes in relapsed\/refractory acute leukemias","volume":"83","author":"Farooq","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.trim.2024.102037_bb0140","first-page":"158","article-title":"Curative efficacy analysis of Allo-HSCT using conditioning regimen of FLAG combined with modified BUCY for refractory and relapsed patients with hematologic malignancies","volume":"19","author":"Wang","year":"2011","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.trim.2024.102037_bb0145","first-page":"576","article-title":"Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan\/cyclophosphamide conditioning regimen for refractory\/relapsed acute myeloid leukemia","volume":"57","author":"Liu","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.trim.2024.102037_bb0150","doi-asserted-by":"crossref","first-page":"38 e31","DOI":"10.1016\/j.jtct.2022.09.003","article-title":"Impact on outcome of minimal residual disease after hematopoietic stem cell transplantation with fludarabine, Amsacrine, and cytosine arabinoside-busulfan conditioning: a retrospective monocentric study","volume":"29","author":"Meur","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.trim.2024.102037_bb0155","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.trim.2024.102037_bb0160","first-page":"1117","article-title":"Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia","volume":"24","author":"Liu","year":"2004","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"key":"10.1016\/j.trim.2024.102037_bb0165","first-page":"65","article-title":"Efficacy and safety of Cladribine-based intensified conditioning regimen in hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia","volume":"30","author":"Pan","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.trim.2024.102037_bb0170","doi-asserted-by":"crossref","first-page":"1014306","DOI":"10.3389\/fphar.2023.1014306","article-title":"Safety and efficacy of a modified busulfan\/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trim.2024.102037_bb0175","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.bbmt.2012.11.005","article-title":"Biology of graft-versus-host responses: recent insights","volume":"19","author":"MacDonald","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.trim.2024.102037_bb0180","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ijc.33595","article-title":"Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: a preliminary study","volume":"149","author":"Hui","year":"2021","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.trim.2024.102037_bb0185","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41409-023-02028-x","volume":"58","author":"Gavriilaki","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102037_bb0190","article-title":"A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trim.2024.102037_bb0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/bmt.2010.114","article-title":"Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY","volume":"46","author":"Naik","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2024.102037_bb0200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1996.d01-1681.x","volume":"93","author":"Ringden","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2024.102037_bb0205","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"Rodriguez-Arboli","year":"2020","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327424000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:55:08Z","timestamp":1716951308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327424000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":41,"alternative-id":["S0966327424000534"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2024.102037","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2024.102037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102037"}}